We are live on ! Find out more
JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

124 hedge funds and large institutions have $378M invested in Jounce Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 32 increasing their positions, 32 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 20

95% more capital invested

Capital invested by funds: $194M → $378M (+$184M)

19% more funds holding

Funds holding: 104 → 124 (+20)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 32

81% less call options, than puts

Call options by funds: $596K | Put options by funds: $3.22M

Holders
124
Holders Change
+20
Holders Change %
+19.23%
% of All Funds
2.18%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
40
Increased
32
Reduced
32
Closed
20
Calls
$596K
Puts
$3.22M
Net Calls
-$2.63M
Net Calls Change
-$2.25M

Top Buyers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
+$35.7M
2
Victory Capital Management
Victory Capital Management
Texas
+$25.7M
3
O
OrbiMed
New York
+$20M
4
CCM
CAAS Capital Management
New York
+$11.5M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$10.5M

Top Sellers

Rank Fund Capital Flow
1
TGI
TRV GP II
Massachusetts
-$29.6M
2
WP
Woodline Partners
California
-$6.59M
3
SI
Sofinnova Investments
California
-$4.53M
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$1.53M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$1.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
CIA
101
Capital Investment Advisors
Georgia
$31K +$32.9K +3,000 New
Royal Bank of Canada
102
Royal Bank of Canada
Ontario, Canada
$23K +$14.3K +1,304 +133%
Citigroup
103
Citigroup
New York
$21K -$26.5K -2,424 -55%
SWM
104
Spire Wealth Management
Virginia
$21K +$21.9K +2,000 New
PHK
105
Point72 Hong Kong
Hong Kong
$21K +$22K +2,009 New
APA
106
American Portfolios Advisors
New York
$16.9K -$1.64K -150 -8%
SPIA
107
Steward Partners Investment Advisory
New York
$16.4K +$17.5K +1,600 New
Legal & General Group
108
Legal & General Group
United Kingdom
$16K – – –
PAM
109
Panagora Asset Management
Massachusetts
$14K – – –
AIP
110
Ameritas Investment Partners
Nebraska
$13K – – –
CB
111
Community Bank
New York
$10K -$11K -1,000 -50%
BG
112
Bollard Group
Massachusetts
$10K – – –
PCM
113
Penserra Capital Management
California
$10K +$931 +85 +9%
MCM
114
MV Capital Management
Maryland
$5K – – –
QT
115
Quantbot Technologies
New York
$3K +$3.95K +361 New
Osaic Holdings
116
Osaic Holdings
Arizona
$1K -$107K -9,799 -99%
Daiwa Securities Group
117
Daiwa Securities Group
Japan
$1K – – –
AIG
118
American International Group
New York
$103 +$296 +27 +0.3%
Nisa Investment Advisors
119
Nisa Investment Advisors
Missouri
$7 – – –
WP
120
Woodline Partners
California
– -$6.59M -940,902 Closed
Verition Fund Management
121
Verition Fund Management
Connecticut
– -$1.21M -172,772 Closed
ZIM
122
Zacks Investment Management
Illinois
– -$1.05M -150,542 Closed
HSA
123
Hussman Strategic Advisors
Maryland
– -$357K -51,000 Closed
ZCM
124
Ziegler Capital Management
Illinois
– -$352K -50,220 Closed
SEI Investments
125
SEI Investments
Pennsylvania
– -$273K -38,935 Closed
2 3 4
5
6

JNCE Hedge Fund Activity: Q1 2021 in Review

124 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q1 2021, worth a combined $378M — up 95% from $194M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new JNCE positions and 20 closed out — a net gain of 20 holders — while 32 added to existing stakes and 32 trimmed.

The largest buyer was PFM Health Sciences, opening a new position worth an estimated $35.7M. The largest seller was TRV GP II, cutting an estimated $29.6M.

  • 124 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q1 2021, up from 104 in Q4 2020.
  • Funds reported $378M of Jounce Therapeutics, Inc. Common Stock stock for Q1 2021, up 95% quarter-over-quarter.
  • 40 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q1 2021 and 20 closed out, a net change of +20 holders.
  • The largest Jounce Therapeutics, Inc. Common Stock buyer in Q1 2021 was PFM Health Sciences, an estimated $35.7M added.
  • The largest Jounce Therapeutics, Inc. Common Stock seller in Q1 2021 was TRV GP II, an estimated $29.6M sold.

Based on aggregated 13F filings for Q1 2021.